Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis

Published:2010-09 Issue:5 Volume:182 Page:684-692
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Van Deun Armand,Maug Aung Kya Jai,Salim Md Abdul Hamid,Das Pankaj Kumar,Sarker Mihir Ranjan,Daru Paul,Rieder Hans L.

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference25 articles.

1. Crunch time for tuberculosis control

2. Multidrug-resistant Tuberculosis Management in Resource-limited Settings

3. Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis

4. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis

5. Ambulatory-Based Standardized Therapy for Multi-Drug Resistant Tuberculosis: Experience from Nepal, 2005–2006

Cited by 588 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Efficacy and Safety of Moxifloxacin and Levofloxacin in a Short Standardised Rifampicin Resistant TB Regimen: A STREAM 2 Secondary Analysis;Tropical Medicine and Infectious Disease;2024-09-11

2. High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial;American Journal of Respiratory and Critical Care Medicine;2024-08-01

3. Mitigating treatment failure of pulmonary pre-extensively drug-resistant tuberculosis: The role of new and repurposed drugs;Journal of Microbiology, Immunology and Infection;2024-08

4. Safety of high-dose amikacin in the first week of all-oral rifampicin-resistant tuberculosis treatment for the prevention of acquired resistance (STAKE): protocol for a single-arm clinical trial;BMJ Open;2024-07

5. Contribution of telacebec to novel drug regimens in a murine tuberculosis model;2024-06-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3